

# [Corrigendum: involvement of a non-human sialic acid in human cancer](https://assignbuster.com/corrigendum-involvement-of-a-non-human-sialic-acid-in-human-cancer/)

[Health & Medicine](https://assignbuster.com/essay-subjects/health-n-medicine/)

A corrigendum on

[Involvement of a non-human sialic acid in human cancer
*by Samraj AN, Läubli H and Varki A. Front Oncol (2014) 4: 33. doi: 10. 3389/fonc. 2014. 00033*](https://www.frontiersin.org/Journal/10.3389/fonc.2014.00033/full)

Antibodies 14F7 and the corresponding anti-idiotype 1E10 (racotumomab, misspelled as racotumumab) were mistakenly conflated in this review. 14F7 reacts with (Neu5Gc)GM3, was recently humanized ( [1](#B1) ), but has not yet been tested in clinical trials. Racotumomab induced a human anti-(Neu5Gc)GM3 immune response, which correlated with longer median survival in non-small cell lung cancer ( [2](#B2) ). The first clinical trial result using racotumomab was actually published in 2002 ( [3](#B3) ). A phase III trial testing racotumomab in advanced non-small cell lung cancer began in 2011, and is currently recruiting (NCT01460472). These studies do not consider dietary Neu5Gc intake and incorporation as a variable that could affect (Neu5Gc)GM3 expression by human cancers.

## Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## References

1. Fernández-Marrero Y, Roque-Navarro L, Hernández T, Dorvignit D, Molina-Pérez M, González A, et al. A cytotoxic humanized anti-ganglioside antibody produced in a murine cell line defective of N-glycolylated-glycoconjugates. *Immunobiology* (2011)216 : 1239–47. doi: 10. 1016/j. imbio. 2011. 07. 004

[Pubmed Abstract](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=21802167) | [Pubmed Full Text](http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?db=pubmed&cmd=prlinks&retmode=ref&id=21802167) | [CrossRef Full Text](http://dx.doi.org/10.1016/j.imbio.2011.07.004)

2. Hernández AM, Toledo D, Martínez D, Griñán T, Brito V, Macías A, et al. Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody. *J Immunol* (2008)181 : 6625–34.

[Pubmed Abstract](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=18941253) | [Pubmed Full Text](http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?db=pubmed&cmd=prlinks&retmode=ref&id=18941253)

3. Alfonso M, Díaz A, Hernández AM, Pérez A, Rodríguez E, Bitton R, et al. An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. *J Immunol* (2002)168 : 2523–9.

[Pubmed Abstract](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=11859147) | [Pubmed Full Text](http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?db=pubmed&cmd=prlinks&retmode=ref&id=11859147)